labetalol (Rx)

Brand and Other Names:Trandate
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injectable solution

  • 5mg/mL

tablet

  • 100mg
  • 200mg
  • 300mg

Hypertension

100 mg PO q12hr initially; increased by 100 mg q12hr every 2-3 days

Usual dosage range: 200-400 mg PO q12hr; not to exceed 2400 mg/day

Hypertensive Emergency

20 mg IV over 2 minutes initially, then 40-80 mg IV q10min; total dose not to exceed 300 mg

Alternative: 1-2 mg/min by continuous IV infusion; total dose of 300 mg has been used

Dosing Modifications

Renal impairment: Not studied; no supplement needed after dialysis

Hepatic impairment: Not studied; dosage reduction may be necessary

Dosing Considerations

Monitor blood pressure every 5-10 minutes

Dosage Forms & Strengths

injectable solution

  • 5mg/mL

tablet

  • 100mg
  • 200mg
  • 300mg

Hypertensive Emergency

0.4-1 mg/kg/hr by continuous IV infusion; not to exceed 3 mg/kg/hr  

Hypertension (Off-label)

1-3 mg/kg/day PO divided q12hr; not to exceed 1200 mg/day  

Alternative: 0.3-1 mg/kg intermittent IV bolus

Next:

Interactions

Interaction Checker

and labetalol

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (1)

            • iobenguane I 123

              labetalol decreases effects of iobenguane I 123 by pharmacodynamic antagonism. Contraindicated. If clinically appropriate, discontinue drugs that decrease uptake of NE for at least 5 half-lives; may cause false-negative imaging results.

            Serious - Use Alternative (19)

            • acebutolol

              acebutolol and labetalol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.

            • atenolol

              atenolol and labetalol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.

            • betaxolol

              betaxolol and labetalol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.

            • bisoprolol

              bisoprolol and labetalol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.

            • carvedilol

              carvedilol and labetalol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.

            • celiprolol

              celiprolol and labetalol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.

            • esmolol

              esmolol and labetalol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.

            • iobenguane I 131

              labetalol will decrease the level or effect of iobenguane I 131 by Other (see comment). Avoid or Use Alternate Drug. Based on the mechanism of action of iobenguane, drugs that reduce catecholamine uptake or that deplete catecholamine stores may interfere with iobenguane uptake into cells, and thus, reduce iobenguane efficacy. Discontinue interfering drugs for at least 5 half-lives before administration of either the dosimetry or an iobenguane dose. Do not administer these drugs until at least 7 days after each iobenguane dose.

            • lofexidine

              lofexidine, labetalol. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid coadministration with other drugs that decrease pulse or blood pressure to mitigate risk of excessive bradycardia and hypotension.

            • metoprolol

              labetalol and metoprolol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.

            • nadolol

              labetalol and nadolol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.

            • nebivolol

              labetalol and nebivolol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.

            • penbutolol

              labetalol and penbutolol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.

            • pindolol

              labetalol and pindolol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.

            • propranolol

              labetalol and propranolol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.

            • sotalol

              labetalol and sotalol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.

            • timolol

              labetalol and timolol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.

            • umeclidinium bromide/vilanterol inhaled

              labetalol, umeclidinium bromide/vilanterol inhaled. pharmacodynamic antagonism. Avoid or Use Alternate Drug. If a beta-blocker must be used in patients with COPD taking a beta-agonist, consider using a beta-blocker that is beta-1 selective .

            • vilanterol/fluticasone furoate inhaled

              labetalol, vilanterol/fluticasone furoate inhaled. pharmacodynamic antagonism. Avoid or Use Alternate Drug. If a beta-blocker must be used in patients with COPD taking a beta-agonist, consider using a beta-blocker that is beta-1 selective .

            Monitor Closely (168)

            • acebutolol

              acebutolol and labetalol both increase serum potassium. Use Caution/Monitor.

            • aceclofenac

              labetalol and aceclofenac both increase serum potassium. Use Caution/Monitor.

              aceclofenac decreases effects of labetalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

            • acemetacin

              labetalol and acemetacin both increase serum potassium. Use Caution/Monitor.

              acemetacin decreases effects of labetalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

            • albuterol

              labetalol increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              labetalol decreases effects of albuterol by pharmacodynamic antagonism. Use Caution/Monitor.

            • aldesleukin

              aldesleukin increases effects of labetalol by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.

            • alfuzosin

              alfuzosin and labetalol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.

            • aluminum hydroxide

              aluminum hydroxide decreases levels of labetalol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.

            • amifostine

              amifostine, labetalol. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration with blood pressure lowering agents may increase the risk and severity of hypotension associated with amifostine. When amifostine is used at chemotherapeutic doses, withhold blood pressure lowering medications for 24 hr prior to amifostine; if blood pressure lowering medication cannot be withheld, do not administer amifostine.

            • amiloride

              labetalol and amiloride both increase serum potassium. Modify Therapy/Monitor Closely.

            • amiodarone

              amiodarone, labetalol. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of cardiotoxicity with bradycardia.

            • amlodipine

              labetalol and amlodipine both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.

            • amobarbital

              amobarbital decreases levels of labetalol by increasing metabolism. Use Caution/Monitor. Consider a higher beta-blocker dose during coadministration of amobarbital. Atenolol, sotalol, nadolol less likely to be affected than other beta blockers.

            • arformoterol

              labetalol increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              labetalol decreases effects of arformoterol by pharmacodynamic antagonism. Use Caution/Monitor.

            • asenapine

              asenapine and labetalol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.

            • aspirin

              labetalol and aspirin both increase serum potassium. Use Caution/Monitor.

              aspirin decreases effects of labetalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

            • aspirin rectal

              labetalol and aspirin rectal both increase serum potassium. Use Caution/Monitor.

              aspirin rectal decreases effects of labetalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

            • aspirin/citric acid/sodium bicarbonate

              aspirin/citric acid/sodium bicarbonate decreases effects of labetalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

              labetalol and aspirin/citric acid/sodium bicarbonate both increase serum potassium. Use Caution/Monitor.

            • atazanavir

              atazanavir increases effects of labetalol by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of hypotension, bradycardia, AV block, and prolonged PR interval. Consider lowering beta blocker dose.

            • atenolol

              atenolol and labetalol both increase serum potassium. Use Caution/Monitor.

            • avanafil

              avanafil increases effects of labetalol by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.

            • bendroflumethiazide

              labetalol increases and bendroflumethiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • betaxolol

              betaxolol and labetalol both increase serum potassium. Use Caution/Monitor.

            • bismuth subsalicylate

              bismuth subsalicylate, labetalol. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Blockage of renal prostaglandin synthesis; may cause severe hypertension.

            • bisoprolol

              bisoprolol and labetalol both increase serum potassium. Use Caution/Monitor.

            • bretylium

              labetalol, bretylium. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Each drug may cause hypotension.

            • bumetanide

              labetalol increases and bumetanide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • butabarbital

              butabarbital decreases levels of labetalol by increasing metabolism. Use Caution/Monitor. Consider a higher beta-blocker dose during coadministration of butabarbital. Atenolol, sotalol, nadolol less likely to be affected than other beta blockers.

            • butalbital

              butalbital decreases levels of labetalol by increasing metabolism. Use Caution/Monitor. Consider a higher beta-blocker dose during coadministration of butalbital. Atenolol, sotalol, nadolol less likely to be affected than other beta blockers.

            • calcium acetate

              calcium acetate decreases effects of labetalol by unspecified interaction mechanism. Use Caution/Monitor.

            • calcium carbonate

              calcium carbonate decreases effects of labetalol by unspecified interaction mechanism. Use Caution/Monitor.

              calcium carbonate decreases levels of labetalol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.

            • calcium chloride

              calcium chloride decreases effects of labetalol by unspecified interaction mechanism. Use Caution/Monitor.

            • calcium citrate

              calcium citrate decreases effects of labetalol by unspecified interaction mechanism. Use Caution/Monitor.

            • calcium gluconate

              calcium gluconate decreases effects of labetalol by unspecified interaction mechanism. Use Caution/Monitor.

            • candesartan

              candesartan and labetalol both increase serum potassium. Use Caution/Monitor.

              labetalol, candesartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.

            • carbenoxolone

              labetalol increases and carbenoxolone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • carbidopa

              carbidopa increases effects of labetalol by pharmacodynamic synergism. Use Caution/Monitor. Therapy with carbidopa, given with or without levodopa or carbidopa-levodopa combination products, is started, dosage adjustment of the antihypertensive drug may be required.

            • carvedilol

              carvedilol and labetalol both increase serum potassium. Use Caution/Monitor.

            • celecoxib

              labetalol and celecoxib both increase serum potassium. Use Caution/Monitor.

              celecoxib decreases effects of labetalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

            • celiprolol

              celiprolol and labetalol both increase serum potassium. Use Caution/Monitor.

            • chlorothiazide

              labetalol increases and chlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • chlorthalidone

              labetalol increases and chlorthalidone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • choline magnesium trisalicylate

              labetalol and choline magnesium trisalicylate both increase serum potassium. Use Caution/Monitor.

              choline magnesium trisalicylate decreases effects of labetalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

            • clevidipine

              labetalol and clevidipine both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.

            • cyclopenthiazide

              labetalol increases and cyclopenthiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • desflurane

              desflurane, labetalol. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.

            • diclofenac

              labetalol and diclofenac both increase serum potassium. Use Caution/Monitor.

              diclofenac decreases effects of labetalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

            • diflunisal

              labetalol and diflunisal both increase serum potassium. Use Caution/Monitor.

              diflunisal decreases effects of labetalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

            • digoxin

              labetalol and digoxin both increase serum potassium. Use Caution/Monitor.

              labetalol increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor. Enhanced bradycardia.

            • diltiazem

              labetalol and diltiazem both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.

            • dobutamine

              labetalol increases and dobutamine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              labetalol decreases effects of dobutamine by pharmacodynamic antagonism. Use Caution/Monitor.

            • dopexamine

              labetalol increases and dopexamine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              labetalol decreases effects of dopexamine by pharmacodynamic antagonism. Use Caution/Monitor.

            • doxazosin

              doxazosin and labetalol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.

            • drospirenone

              labetalol and drospirenone both increase serum potassium. Modify Therapy/Monitor Closely.

            • ephedrine

              labetalol increases and ephedrine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              labetalol decreases effects of ephedrine by pharmacodynamic antagonism. Use Caution/Monitor.

            • epinephrine

              labetalol increases and epinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              labetalol decreases effects of epinephrine by pharmacodynamic antagonism. Use Caution/Monitor.

            • epinephrine racemic

              labetalol increases and epinephrine racemic decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              labetalol decreases effects of epinephrine racemic by pharmacodynamic antagonism. Use Caution/Monitor.

            • eprosartan

              eprosartan and labetalol both increase serum potassium. Use Caution/Monitor.

              labetalol, eprosartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.

            • esmolol

              esmolol and labetalol both increase serum potassium. Use Caution/Monitor.

            • ethacrynic acid

              labetalol increases and ethacrynic acid decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • ether

              labetalol, ether. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both beta blockers and ether depress the myocardium; consider lowering beta blocker dose if ether used for anesthesia.

            • etodolac

              labetalol and etodolac both increase serum potassium. Use Caution/Monitor.

              etodolac decreases effects of labetalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

            • etomidate

              etomidate, labetalol. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.

            • felodipine

              labetalol and felodipine both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.

            • fenbufen

              labetalol and fenbufen both increase serum potassium. Use Caution/Monitor.

            • fenoprofen

              labetalol and fenoprofen both increase serum potassium. Use Caution/Monitor.

              fenoprofen decreases effects of labetalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

            • fingolimod

              labetalol increases effects of fingolimod by pharmacodynamic synergism. Use Caution/Monitor. Both medications decrease heart rate. Monitor patients on concomitant therapy, particularly in the first 6 hours after fingolimod is initiated or after a treatment interruption of at least two weeks, for bradycardia and atrioventricular block. To identify underlying risk factors of bradycardia and AV block, obtain a new or recent ECG in patients using beta-blockers prior to starting fingolimod.

            • flurbiprofen

              labetalol and flurbiprofen both increase serum potassium. Use Caution/Monitor.

              flurbiprofen decreases effects of labetalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

            • formoterol

              labetalol increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              labetalol decreases effects of formoterol by pharmacodynamic antagonism. Use Caution/Monitor.

            • furosemide

              labetalol increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • gentamicin

              labetalol increases and gentamicin decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • glucagon

              glucagon decreases toxicity of labetalol by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Coadministration of glucagon with beta-blockers may have transiently increased pulse and blood pressure.

            • glucagon intranasal

              glucagon intranasal decreases toxicity of labetalol by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Coadministration of glucagon with beta-blockers may have transiently increased pulse and blood pressure.

            • hydralazine

              hydralazine increases effects of labetalol by pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects.

            • hydrochlorothiazide

              labetalol increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • ibuprofen

              labetalol and ibuprofen both increase serum potassium. Use Caution/Monitor.

              ibuprofen decreases effects of labetalol by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs diminish antihypertensive effects of beta-blockers.

            • ibuprofen IV

              ibuprofen IV decreases effects of labetalol by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs diminish antihypertensive effects of beta-blockers.

              labetalol and ibuprofen IV both increase serum potassium. Use Caution/Monitor.

            • indapamide

              labetalol increases and indapamide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • indomethacin

              labetalol and indomethacin both increase serum potassium. Use Caution/Monitor.

              indomethacin decreases effects of labetalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

            • insulin degludec

              labetalol, insulin degludec. Other (see comment). Modify Therapy/Monitor Closely. Comment: Beta-blockers may either increase or decrease the blood glucose lowering effect of insulin; beta-blockers can prolong hypoglycemia (interference with glycogenolysis) or cause hyperglycemia (insulin secretion inhibited).

            • insulin degludec/insulin aspart

              labetalol, insulin degludec/insulin aspart. Other (see comment). Modify Therapy/Monitor Closely. Comment: Beta-blockers may either increase or decrease the blood glucose lowering effect of insulin; beta-blockers can prolong hypoglycemia (interference with glycogenolysis) or cause hyperglycemia (insulin secretion inhibited).

            • insulin inhaled

              labetalol, insulin inhaled. Other (see comment). Modify Therapy/Monitor Closely. Comment: Beta-blockers may either increase or decrease the blood glucose lowering effect of insulin; beta-blockers can prolong hypoglycemia (interference with glycogenolysis) or cause hyperglycemia (insulin secretion inhibited).

            • iodixanol

              labetalol increases toxicity of iodixanol by unspecified interaction mechanism. Use Caution/Monitor. Use of beta-blockers lowers the threshold for and increases the severity of contrast reactions, and reduces the responsiveness of treatment of hypersensitivity reactions with epinephrine. .

            • irbesartan

              irbesartan and labetalol both increase serum potassium. Use Caution/Monitor.

              labetalol, irbesartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.

            • isoproterenol

              labetalol increases and isoproterenol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              labetalol decreases effects of isoproterenol by pharmacodynamic antagonism. Use Caution/Monitor.

            • isradipine

              labetalol and isradipine both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.

            • ivabradine

              ivabradine, labetalol. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Most patients receiving ivabradine will also be treated with a beta-blocker. The risk of bradycardia increases with coadministration of drugs that slow heart rate (eg, digoxin, amiodarone, beta-blockers). Monitor heart rate in patients taking ivabradine with other negative chronotropes.

            • ketamine

              ketamine, labetalol. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.

            • ketoprofen

              labetalol and ketoprofen both increase serum potassium. Use Caution/Monitor.

              ketoprofen decreases effects of labetalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

            • ketorolac

              labetalol and ketorolac both increase serum potassium. Use Caution/Monitor.

              ketorolac decreases effects of labetalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

            • ketorolac intranasal

              labetalol and ketorolac intranasal both increase serum potassium. Use Caution/Monitor.

              ketorolac intranasal decreases effects of labetalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

            • lasmiditan

              labetalol increases effects of lasmiditan by pharmacodynamic synergism. Use Caution/Monitor. Lasmiditan has been associated with a lowering of heart rate (HR). In a drug interaction study, addition of a single 200-mg dose of lasmiditan to propranolol decreased HR by an additional 5 bpm compared to propranolol alone, for a mean maximum of 19 bpm.

            • levalbuterol

              labetalol increases and levalbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              labetalol decreases effects of levalbuterol by pharmacodynamic antagonism. Use Caution/Monitor.

            • levodopa

              levodopa increases effects of labetalol by pharmacodynamic synergism. Use Caution/Monitor. Consider decreasing dosage of antihypertensive agent.

            • lornoxicam

              labetalol and lornoxicam both increase serum potassium. Use Caution/Monitor.

              lornoxicam decreases effects of labetalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

            • losartan

              losartan and labetalol both increase serum potassium. Use Caution/Monitor.

              labetalol, losartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.

            • lurasidone

              lurasidone increases effects of labetalol by Other (see comment). Use Caution/Monitor. Comment: Potential for increased risk of hypotension with concurrent use. Monitor blood pressure and adjust dose of antihypertensive agent as needed.

            • maraviroc

              maraviroc, labetalol. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of orthostatic hypotension.

            • meclofenamate

              meclofenamate decreases effects of labetalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

              labetalol and meclofenamate both increase serum potassium. Use Caution/Monitor.

            • mefenamic acid

              labetalol and mefenamic acid both increase serum potassium. Use Caution/Monitor.

              mefenamic acid decreases effects of labetalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

            • mefloquine

              mefloquine increases levels of labetalol by decreasing metabolism. Use Caution/Monitor. Risk of arrhythmia.

            • meloxicam

              labetalol and meloxicam both increase serum potassium. Use Caution/Monitor.

              meloxicam decreases effects of labetalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

            • metaproterenol

              labetalol increases and metaproterenol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              labetalol decreases effects of metaproterenol by pharmacodynamic antagonism. Use Caution/Monitor.

            • methyclothiazide

              labetalol increases and methyclothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor. .

            • metolazone

              labetalol increases and metolazone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • metoprolol

              labetalol and metoprolol both increase serum potassium. Use Caution/Monitor.

            • mipomersen

              mipomersen, labetalol. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Both drugs have potential to increase hepatic enzymes; monitor LFTs.

            • moxisylyte

              moxisylyte and labetalol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.

            • nabumetone

              labetalol and nabumetone both increase serum potassium. Use Caution/Monitor.

              nabumetone decreases effects of labetalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

            • nadolol

              labetalol and nadolol both increase serum potassium. Use Caution/Monitor.

            • naproxen

              labetalol and naproxen both increase serum potassium. Use Caution/Monitor.

              naproxen decreases effects of labetalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

            • nebivolol

              labetalol and nebivolol both increase serum potassium. Use Caution/Monitor.

            • nicardipine

              labetalol and nicardipine both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.

            • nifedipine

              labetalol and nifedipine both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.

            • nisoldipine

              labetalol and nisoldipine both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.

            • nitroglycerin rectal

              nitroglycerin rectal, labetalol. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Beta-blockers blunt the reflex tachycardia produced by nitroglycerin without preventing its hypotensive effects. If beta-blockers are used with nitroglycerin in patients with angina pectoris, additional hypotensive effects may occur.

            • norepinephrine

              labetalol increases and norepinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              labetalol decreases effects of norepinephrine by pharmacodynamic antagonism. Use Caution/Monitor.

            • olmesartan

              olmesartan and labetalol both increase serum potassium. Use Caution/Monitor.

              labetalol, olmesartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.

            • olodaterol inhaled

              labetalol, olodaterol inhaled. Either decreases effects of the other by pharmacodynamic antagonism. Use Caution/Monitor. Beta-blockers and olodaterol may interfere with the effect of each other when administered concurrently. Beta-blockers may produce severe bronchospasm in COPD patients. Therefore, patients with COPD should not normally be treated with beta-blockers. However, under certain circumstances, e.g. as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-blockers in patients with COPD. In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution.

            • oxaprozin

              labetalol and oxaprozin both increase serum potassium. Use Caution/Monitor.

              oxaprozin decreases effects of labetalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

            • oxymetazoline topical

              oxymetazoline topical increases and labetalol decreases sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • parecoxib

              labetalol and parecoxib both increase serum potassium. Use Caution/Monitor.

              parecoxib decreases effects of labetalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

            • penbutolol

              labetalol and penbutolol both increase serum potassium. Use Caution/Monitor.

            • pentobarbital

              pentobarbital decreases levels of labetalol by increasing metabolism. Use Caution/Monitor. Consider a higher beta-blocker dose during coadministration of pentobarbital. Atenolol, sotalol, nadolol less likely to be affected than other beta blockers.

            • phenobarbital

              phenobarbital decreases levels of labetalol by increasing metabolism. Use Caution/Monitor. Consider a higher beta-blocker dose during coadministration of phenobarbital. Atenolol, sotalol, nadolol less likely to be affected than other beta blockers.

            • phenoxybenzamine

              phenoxybenzamine and labetalol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.

            • phentolamine

              phentolamine and labetalol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.

            • pindolol

              labetalol and pindolol both increase serum potassium. Use Caution/Monitor.

            • pirbuterol

              labetalol increases and pirbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              labetalol decreases effects of pirbuterol by pharmacodynamic antagonism. Use Caution/Monitor.

            • piroxicam

              labetalol and piroxicam both increase serum potassium. Use Caution/Monitor.

              piroxicam decreases effects of labetalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

            • ponesimod

              ponesimod and labetalol both increase pharmacodynamic synergism. Use Caution/Monitor. Beta-blockers may have additive effects on lowering HR. Consider resting HR before initiating ponesimod in patients on stable dose of beta-blocker. Refer to the ponesimod prescribing information for more dosing information.

            • potassium acid phosphate

              labetalol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

            • potassium chloride

              labetalol and potassium chloride both increase serum potassium. Modify Therapy/Monitor Closely.

            • potassium citrate

              labetalol and potassium citrate both increase serum potassium. Modify Therapy/Monitor Closely.

            • prazosin

              prazosin and labetalol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.

            • primidone

              primidone decreases levels of labetalol by increasing metabolism. Use Caution/Monitor. Consider a higher beta-blocker dose during coadministration of primidone. Atenolol, sotalol, nadolol less likely to be affected than other beta blockers.

            • propofol

              propofol, labetalol. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.

            • propranolol

              labetalol and propranolol both increase serum potassium. Use Caution/Monitor.

            • sacubitril/valsartan

              sacubitril/valsartan and labetalol both increase serum potassium. Use Caution/Monitor.

              labetalol, sacubitril/valsartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.

            • salicylates (non-asa)

              labetalol and salicylates (non-asa) both increase serum potassium. Use Caution/Monitor.

              salicylates (non-asa) decreases effects of labetalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

            • salmeterol

              labetalol increases and salmeterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              labetalol decreases effects of salmeterol by pharmacodynamic antagonism. Use Caution/Monitor.

            • salsalate

              labetalol and salsalate both increase serum potassium. Use Caution/Monitor.

              salsalate decreases effects of labetalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

            • saquinavir

              saquinavir, labetalol. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Use alternatives if available. Increased risk of PR or QT prolongation and cardiac arrhythmias.

            • secobarbital

              secobarbital decreases levels of labetalol by increasing metabolism. Use Caution/Monitor. Consider a higher beta-blocker dose during coadministration of secobarbital. Atenolol, sotalol, nadolol less likely to be affected than other beta blockers.

            • sevoflurane

              sevoflurane, labetalol. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.

            • sildenafil

              labetalol increases effects of sildenafil by additive vasodilation. Use Caution/Monitor. Sildenafil has systemic vasodilatory properties and may further lower blood pressure in patients taking antihypertensive medications. Monitor blood pressure response to sildenafil in patients receiving concurrent blood pressure lowering therapy.

            • silodosin

              silodosin and labetalol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.

            • siponimod

              siponimod, labetalol. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Caution when siponimod is initiated in patients receiving beta-blocker treatment because of additive effects on lowering heart rate. Temporary interruption of beta-blocker may be needed before initiating siponimod. Beta-blocker treatment can be initiated in patients receiving stable doses of siponimod.

            • sodium bicarbonate

              sodium bicarbonate decreases levels of labetalol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.

            • sodium citrate/citric acid

              sodium citrate/citric acid decreases levels of labetalol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.

            • sotalol

              labetalol and sotalol both increase serum potassium. Use Caution/Monitor.

            • spironolactone

              labetalol and spironolactone both increase serum potassium. Modify Therapy/Monitor Closely.

            • succinylcholine

              labetalol and succinylcholine both increase serum potassium. Use Caution/Monitor.

            • sulfasalazine

              labetalol and sulfasalazine both increase serum potassium. Use Caution/Monitor.

              sulfasalazine decreases effects of labetalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

            • sulindac

              labetalol and sulindac both increase serum potassium. Use Caution/Monitor.

              sulindac decreases effects of labetalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

            • tadalafil

              tadalafil increases effects of labetalol by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.

            • telmisartan

              telmisartan and labetalol both increase serum potassium. Use Caution/Monitor.

              labetalol, telmisartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.

            • terazosin

              terazosin and labetalol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.

            • terbutaline

              labetalol increases and terbutaline decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              labetalol decreases effects of terbutaline by pharmacodynamic antagonism. Use Caution/Monitor.

            • theophylline

              labetalol, theophylline. Other (see comment). Use Caution/Monitor. Comment: Beta blockers (esp. non selective) antagonize theophylline effects, while at the same time increasing theophylline levels and toxicity (mechanism: decreased theophylline metabolism). Smoking increases risk of interaction.

            • timolol

              labetalol and timolol both increase serum potassium. Use Caution/Monitor.

            • tolfenamic acid

              labetalol and tolfenamic acid both increase serum potassium. Use Caution/Monitor.

              tolfenamic acid decreases effects of labetalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

            • tolmetin

              labetalol and tolmetin both increase serum potassium. Use Caution/Monitor.

              tolmetin decreases effects of labetalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.

            • tolvaptan

              labetalol and tolvaptan both increase serum potassium. Use Caution/Monitor.

            • torsemide

              labetalol increases and torsemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • triamterene

              labetalol and triamterene both increase serum potassium. Modify Therapy/Monitor Closely.

            • valsartan

              valsartan and labetalol both increase serum potassium. Use Caution/Monitor.

              labetalol, valsartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.

            • verapamil

              labetalol and verapamil both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.

            • xipamide

              xipamide increases effects of labetalol by pharmacodynamic synergism. Use Caution/Monitor.

            Minor (32)

            • adenosine

              labetalol, adenosine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Bradycardia.

            • agrimony

              agrimony increases effects of labetalol by pharmacodynamic synergism. Minor/Significance Unknown.

            • atosiban

              atosiban decreases levels of labetalol by unspecified interaction mechanism. Minor/Significance Unknown.

            • brimonidine

              brimonidine increases effects of labetalol by pharmacodynamic synergism. Minor/Significance Unknown.

            • cevimeline

              cevimeline increases effects of labetalol by unspecified interaction mechanism. Minor/Significance Unknown.

            • cocaine

              labetalol increases effects of cocaine by pharmacodynamic synergism. Minor/Significance Unknown. Risk of angina.

            • cornsilk

              cornsilk increases effects of labetalol by pharmacodynamic synergism. Minor/Significance Unknown.

            • diazepam

              labetalol increases effects of diazepam by decreasing metabolism. Minor/Significance Unknown.

            • dihydroergotamine

              dihydroergotamine, labetalol. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Additive vasospasm.

            • dihydroergotamine intranasal

              dihydroergotamine intranasal, labetalol. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Additive vasospasm.

            • dipyridamole

              dipyridamole, labetalol. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of bradycardia.

            • escitalopram

              escitalopram increases levels of labetalol by decreasing metabolism. Minor/Significance Unknown.

            • fenoldopam

              fenoldopam increases effects of labetalol by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.

            • forskolin

              forskolin increases effects of labetalol by pharmacodynamic synergism. Minor/Significance Unknown.

            • imaging agents (gadolinium)

              labetalol, imaging agents (gadolinium). Mechanism: unknown. Minor/Significance Unknown. Increased risk of anaphylaxis from contrast media.

            • levobetaxolol

              levobetaxolol increases effects of labetalol by pharmacodynamic synergism. Minor/Significance Unknown.

            • maitake

              maitake increases effects of labetalol by pharmacodynamic synergism. Minor/Significance Unknown.

            • melatonin

              melatonin decreases toxicity of labetalol by pharmacodynamic antagonism. Minor/Significance Unknown. Melatonin may correct beta blocker induced sleep disturbances.

            • metipranolol ophthalmic

              metipranolol ophthalmic increases effects of labetalol by pharmacodynamic synergism. Minor/Significance Unknown.

            • neostigmine

              labetalol, neostigmine. Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive bradycardia.

            • noni juice

              labetalol and noni juice both increase serum potassium. Minor/Significance Unknown.

            • octacosanol

              octacosanol increases effects of labetalol by pharmacodynamic synergism. Minor/Significance Unknown.

            • oxazepam

              labetalol increases effects of oxazepam by decreasing metabolism. Minor/Significance Unknown.

            • physostigmine

              labetalol, physostigmine. Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive bradycardia.

            • pilocarpine

              pilocarpine increases effects of labetalol by pharmacodynamic synergism. Minor/Significance Unknown.

            • reishi

              reishi increases effects of labetalol by pharmacodynamic synergism. Minor/Significance Unknown.

            • shepherd's purse

              shepherd's purse, labetalol. Other (see comment). Minor/Significance Unknown. Comment: Theoretically, shepherd's purse may interfere with BP control.

            • sildenafil

              sildenafil increases effects of labetalol by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypotension.

            • tizanidine

              tizanidine increases effects of labetalol by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypotension.

            • treprostinil

              treprostinil increases effects of labetalol by pharmacodynamic synergism. Minor/Significance Unknown.

            • vardenafil

              vardenafil increases effects of labetalol by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypotension.

            • yohimbe

              labetalol decreases toxicity of yohimbe by pharmacodynamic antagonism. Minor/Significance Unknown.

            Previous
            Next:

            Adverse Effects

            >10%

            Dizziness (1-20%)

            Lightheadedness (1-20%)

            Nausea (≤19%)

            Tingling sensation of scalp (4-12%)

            Fatigue (1-11%)

            1-10%

            Elevated serum blood urea nitrogen (BUN) (≤8%)

            Elevated serum creatinine (8%)

            Congestion of nasal sinus (1-6%)

            Orthostatic hypotension (1-5%)

            Absence of ejaculation (<5%)

            Paresthesia (<5%)

            Elevated liver enzymes (4%)

            Diaphoresis (≤4%)

            Edema (≤2%)

            Bronchospasm (1-2%)

            Dyspnea (1-2%)

            Pruritus (1%)

            Rash (1%)

            Altered taste sense (1%)

            Ventricular arrhythmia (1%; IV)

            Frequency Not Defined

            Angioedema

            Bradycardia

            Alopecia

            Cholestatic jaundice

            Depression

            Diabetes insipidus

            Hepatitis

            Raynaud syndrome

            Toxic myopathy

            Urinary retention

            Urticaria

            Raynaud phenomenon

            Previous
            Next:

            Warnings

            Contraindications

            Asthma or obstructive airway disease, severe bradycardia, 2°/3° heart block (without pacemaker), cardiogenic shock, bronchial asthma, uncompensated cardiac failure, hypersensitivity, sinus bradycardia, sick sinus syndrome without permanent pacemaker; conditions associated with prolonged and severe hypotension

            Cautions

            Use with caution in anesthesia or surgery (myocardial depression), bronchospastic disease (not recommended), cerebrovascular insufficiency, diabetes mellitus, hyperthyroidism or thyrotoxicosis, hepatic impairment, renal impairment, peripheral vascular disease, compromised left ventricular function, advanced age, heart failure, pheochromocytoma

            Increased risk of stroke after surgery

            Severe hepatic injury reported with use; with prolonged use, monitor liver function tests

            Sudden discontinuance can exacerbate angina and lead to myocardial infarction

            Use with caution in patients taking calcium channel blockers, cardiac glycosides, or inhaled anesthetics

            Intraoperative floppy iris syndrome observed during cataract surgery in some patients treated with alpha1 blockers (labetalol is both an alpha and a beta blocker)

            Hypotension with or without syncope may occur; monitor

            Consider pre-existing conditions, such as, sick sinus syndrome before initiating therapy

            Use caution in patients with history of severe anaphylaxis to allergens; patients taking beta-blockers may become more sensitive to repeated challenges; treatment with epinephrine in patients taking beta-blockers may be ineffective or promote undesirable effects

            Use with caution in patients with myasthenia gravis, psoriasis, or psychiatric illness (may cause or exacerbate CNS depression)

            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy category: C

            Lactation: Small amounts excreted; use with caution

            Pregnancy Categories

            A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA: Information not available.

            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Nonselective beta blocker with intrinsic sympathomimetic activity; also alpha blocker

            Absorption

            Bioavailability: 25% (PO)

            Onset: PO, 20-120 min; IV, 2.5 min

            Duration: 100 mg, 8 hr; 300 mg, 12 hr

            Peak plasma time: 1-2 hr (PO)

            Peak effect: 15 min (IV); 1-4 hr (PO)

            Distribution

            Protein bound: 50%

            Vd: 3-16 L/kg (adults)

            Metabolism

            Metabolized mainly through conjugation to glucuronide metabolites

            Elimination

            Half-life: 6-8 hr (PO); 5.5 hr (IV)

            Excretion: Urine (55-60%), feces via bile

            Previous
            Next:

            Administration

            IV Compatibilities

            Solution: Compatible with most common solvents

            Y-site: Alcohol 10% in D5W, amikacin, aminophylline, amiodarone, ampicillin, bivalirudin, butorphanol, calcium gluconate, cefazolin, ceftazidime, ceftizoxime, chloramphenicol, cimetidine, clindamycin, dexmedetomidine, diltiazem, dobutamine, dopamine, enalaprilat, epinephrine, erythromycin, esmolol, famotidine, fenoldopam, fentanyl, gatifloxacin, gentamicin, heparin (incompatible at 5 mg/mL), hetastarch, hydromorphone, insulin (?), lidocaine, linezolid, lorazepam, magnesium sulfate, meperidine, metronidazole, midazolam, milrinone, morphine, nicardipine, nitroglycerin, norepinephrine, oxacillin, penicillin G, piperacillin, potassium chloride, potassium phosphates, propofol, ranitidine, sodium acetate, sodium nitroprusside, tobramycin, trimethoprim-sulfamethoxazole, vancomycin, vecuronium

            IV Incompatibilities

            Solution: Sodium bicarbonate 5%

            Y-site: Amphotericin B cholesteryl sulfate, cefoperazone, ceftriaxone, furosemide, nafcillin, thiopental, warfarin

            IV Preparation

            Standard diluent: 500 mg/250 mL D5W

            Minimum volume: 250 mL D5W

            IV Administration

            Requires infusion pump

            Slow direct IV push administered over 2 minutes

            Loading infusions (2 mg/min) require close monitoring of HR and BP and are terminated after response occurs or a cumulative dose of 300 mg is reached

            Continuous infusions of 2-6 mg/hr have been used in some settings and should not be confused with loading infusions

            Storage

            Store at room temperature or under refrigeration (2-30°C [36-86°F])

            Protect from light and freezing

            Solution is clear to slightly yellow

            Previous
            Next:

            Images

            BRAND FORM. UNIT PRICE PILL IMAGE
            labetalol intravenous
            -
            5 mg/mL vial
            labetalol intravenous
            -
            5 mg/mL vial
            labetalol intravenous
            -
            5 mg/mL vial
            labetalol intravenous
            -
            5 mg/mL vial
            labetalol intravenous
            -
            5 mg/mL vial
            labetalol intravenous
            -
            5 mg/mL vial
            labetalol intravenous
            -
            5 mg/mL vial
            labetalol intravenous
            -
            5 mg/mL vial
            labetalol intravenous
            -
            20 mg/4 mL (5 mg/mL) solution
            labetalol intravenous
            -
            5 mg/mL vial
            labetalol oral
            -
            100 mg tablet
            labetalol oral
            -
            200 mg tablet
            labetalol oral
            -
            300 mg tablet
            labetalol oral
            -
            300 mg tablet
            labetalol oral
            -
            200 mg tablet
            labetalol oral
            -
            100 mg tablet
            labetalol oral
            -
            200 mg tablet
            labetalol oral
            -
            100 mg tablet
            labetalol oral
            -
            300 mg tablet
            labetalol oral
            -
            300 mg tablet
            labetalol oral
            -
            100 mg tablet
            labetalol oral
            -
            100 mg tablet
            labetalol oral
            -
            200 mg tablet
            labetalol oral
            -
            100 mg tablet
            labetalol oral
            -
            200 mg tablet
            labetalol oral
            -
            300 mg tablet
            labetalol oral
            -
            300 mg tablet
            labetalol oral
            -
            100 mg tablet
            labetalol oral
            -
            200 mg tablet
            labetalol oral
            -
            100 mg tablet
            labetalol oral
            -
            300 mg tablet
            labetalol oral
            -
            200 mg tablet
            labetalol oral
            -
            200 mg tablet
            labetalol oral
            -
            300 mg tablet

            Copyright © 2010 First DataBank, Inc.

            Previous
            Next:

            Patient Handout

            Select a drug:
            Patient Education
            labetalol intravenous

            NO MONOGRAPH AVAILABLE AT THIS TIME

            USES: Consult your pharmacist.

            HOW TO USE: Consult your pharmacist.

            SIDE EFFECTS: Consult your pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

            PRECAUTIONS: Consult your pharmacist.

            DRUG INTERACTIONS: Consult your pharmacist.Keep a list of all your medications with you, and share the list with your doctor and pharmacist.

            OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.

            NOTES: No monograph available at this time.

            MISSED DOSE: Consult your pharmacist.

            STORAGE: Consult your pharmacist.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.

            Information last revised July 2016. Copyright(c) 2021 First Databank, Inc.

            IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.